Patent Grant
7816520
The present invention relates to 5,6-diphenyl-1,2,4-triazine derivatives, and in particular to the use thereof as sun filters on human skin and hair or as light-protective agents in the synthetic materials industry such as plastics, glass and textiles. The present invention also has as an object cosmetic compositions containing the aforesaid derivatives.
As a brief review, the action of solar radiation on the skin depends primarily on the energy of the radiation which reaches the various cutaneous layers. Generally speaking, the most energetic radiation, i.e., having the shortest wavelength (E=hc/λ), cause erythemas or “sunburn”, whereas less energetic radiation only causes a simple browning of the skin. It is thus considered that a sun filter intended to be part of the composition of so-called “sunscreen” cosmetic preparations must absorb short wavelength radiation to the maximum degree possible while remaining transparent to radiation of longer wavelength.
Photobiologists typically divide the ultraviolet spectrum into three parts, called UV-A, UV-B and UV-C, which correspond to the decreasing wavelength ranges from 400 nm to 320 nm, from 320 nm to 280 nm and from 280 nm to 200 nm, respectively.
UV-B and UV-A allow the tanning of the human epidermis. UV-B causes erythemas and cutaneous burns which can harm the development of a natural tan. For these reasons, as well as for esthetic reasons, a constant demand exists for methods of controlling this natural tanning with a view to controlling the color of the skin. It is thus advisable to filter this UV-B radiation.
It is also known that UV-A rays are likely to induce a deterioration of the skin, in particular in the case of sensitive skin or skin continuously exposed to sun radiation. In particular, UV-A rays cause a loss of skin elasticity and the appearance of wrinkles which lead to premature aging. They cause the triggering of the erythematous reaction or amplify this reaction in certain subjects and can even be the cause of phototoxic or photoallergic reactions. It is thus desirable to UV filter-A radiation as well.
UV-C, which is the most highly energetic, causes photokeratitis. The ozone formed in the stratosphere generally absorbs a large part of this UV-C radiation which, on the other hand, is found in large amounts in the radiation emitted by artificial lamps, which are often responsible for serious cutaneous injuries. UV-B, which penetrates the skin layer and, in particular, the stratum mucosum of the epidermis, causes solar erythemas. Consequently, UV-B and UV-C radiation together constitute the so-called erythema spectrum with regard to which sun filters must act as a screen. UV-A produces the direct pigmentation of the skin (melanogenesis), i.e., the tanning of the skin.
Compounds derived from the benzotriazoles and/or the benzotriazoles are known as UV filters, in particular in the field of cosmetics. The patent application FR 2,803,194 thus disclosed S-triazine derivatives carrying phenylbenzothiazole or benzothiazole groups useful as UV filters in particulate form. These compounds cover the range of UV-A and of UV-B but they exhibit the major disadvantage of absorbing in the visible spectrum (wavelengths longer than 400 nm). Thus these products are heavily colored, which limits their use in cosmetic products.
The present invention proposes novel 5,6-diphenyl-1,2,4-triazine derivatives capable of absorbing in UV-A and/or UV-B and/or UV-C, without absorbing in the visible spectrum. Thus these compounds have the advantage of being lightly colored.
They also have the advantage of being capable of being specific to one of these spectra. This is advantageous when it is desired to filter a specific UV spectra (UV-A, UV-B or UV-C), for example to supplement the spectral effectiveness of a UV filter which exhibits a gap in this specific range.
These novel derivatives thus offer a varied range of specific UV filters which can also exhibit various degrees of absorbance. The combination of several of these filters selected according to their specificity and their degree of absorbance thus makes it possible to prepare all types of UV filters acting in the spectrum and with the absorbance desired.
These novel derivatives also have the advantage of being soluble in various pharmaceutically acceptable excipients and of exhibiting better photostability than certain commercial filters, which makes them particularly useful in cosmetic products, notably in sun protectors.
The present invention has as an object the 5,6-diphenyl-1,2,4-triazinic compounds of general formula (I):
wherein:
Among the compounds of general formula (I), the following compounds have led to particularly advantageous practical results:
The present invention also has as an object cosmetic sunscreen compositions containing an effective quantity of at least one compound of formula (I) in combination with a cosmetically acceptable excipient, preferably between 0.1% and 20% by weight with respect to the total weight of the composition.
The cosmetic sunscreen compositions according to the invention may contain in addition one or more sun filters active in UV-A and/or UV-B and/or UV-C (absorbers), either hydrophilic or lipophilic. These additional filters may be selected among, in particular, cinnamic derivatives, dibenzoylmethane derivatives, salicylic derivatives, camphor derivatives and triazine derivatives other than those previously cited in the present invention.
The present invention also has as an object the use, as sun filters active in UV-A and/or UV-B and/or UV-C for human skin and/or hair, of 5,6-diphenyl-1,2,4-triazinic compounds of general formula (I):
wherein:
The present invention also has as an object the use of compounds such as previously defined as light-protective agents active in the UV-A and/or UV-B and/or UV-C spectra, useful in the synthetic materials industry, in particular as light-protective agents incorporated into the composition of plastics, glass or textiles.
These compounds, which are objects of the present invention, can thus be used to protect photosensitive materials.
The light-protective agent could be incorporated into a substratum with the goal of protecting said substratum against attack from ultraviolet rays, to prevent the modification of one or several physical properties of said substratum, such as, for example, discoloration, a change in resistance to tearing, an increase in brittleness, etc., and/or to prevent chemical reactions caused by ultraviolet rays, for example the oxidation process. In this case, the protective agent can be incorporated before and during the preparation of the substratum, or at a later time by a suitable process, for example a binding process analogous to dyeing.
The light-protective agent can also be incorporated into a substratum to protect one or more additional substances incorporated into the aforesaid substratum, for example dyes, auxiliary agents, etc.
The light-protective agent can also be incorporated into a filter layer that may be a solid (film, sheet) or semi-solid (cream, oil, wax) applied to a substratum for the purpose of protecting said substratum from ultraviolet rays.
The compounds of the present invention are suitable not only as light-protective agents for colorless materials, but also for pigmented materials. In this case, the protection against light is extended to the coloring agents, thus allowing in many cases a quite notable improvement of stability in light.
The compounds of general formula (I) can be prepared from 1,2-diketones of formula (II), by conventional methods known to those skilled in the art, such as those described in the examples which follow.
in which R1 and R2 have the same significance as that given previously.
The diketones of formula (II) are available commercially (such as, for example, benzyl(diphenylethan-1,2-dione), 4,4′-dimethylbenzyl, 4,4′-dibromobenzyl, 4,4′-difluorobenzyl or 4,4′-dichlorobenzyl) or can be synthesized by conventional methods well known to those skilled in the art. For example, the following synthesis route can be used:
The examples which follow give other examples of syntheses of diketones of formula (II).
The present invention will be illustrated below by mentioning several nonrestrictive examples of the preparation of representative derivatives conforming to general formula (I).
The compounds prepared are summarized in table 1.
The compounds of formula (I) of table 1 can be synthesized in the following way:
wherein R1, R2=hydrogen, halogen,
DMB=Parsol 1798® (Roche Laboratories)
MCX=Parsol MCX® (Roche Laboratories)
Oxalyl chloride (4.71 ml, 55.2 mmol) at 0° C. is slowly added to a mixture of anisole (10.8 g, 100 mmol) and aluminum chloride (33.33 g, 250 mmol). The mixture is stirred at ambient temperature for 4 hours. After cooling, it is poured into iced water and extracted with dichloromethane. The organic phases collected are washed with 2 N HCl then with brine and are dried on magnesium sulfate. After filtration and concentration under reduced pressure, the residue is recrystallized in ethanol. The resulting precipitate is filtered, washed several times in ethanol and dried to yield 9.80 g (66%) of pure product in the form of a yellow solid. δH (200 MHz, CDCl3) 3.93 (s; 6H), 6.99 (d; J 7.8; 4H), 7.99 (d; J 7.8; 4H).
A suspension of terephthalonitrile (12.81 g, 100 mmol) in absolute ethanol (250 ml) cooled to 0° C. is bubbled with HCl gas for 18 hours, during which the temperature rises to ambient temperature. The white solid obtained (27.5 g of dichlorohydrate salt) is then filtered and washed with ethanol. The neutralization of this salt, dissolved in a minimum of water at 0° C., is carried out by adding a potash solution (15% aqueous) up to basic pH. A white solid is obtained (yield>90%) after filtration, successive washes with water then with pentane and drying. mp 158-161° C.; δH (300 MHz, CDCl3) 1.43 (t; J 7.2; 6H), 4.32 (q; J 7.2; 4H), 7.79 (s; 4H); SM (Electrospray) m/z 222 (40%), 221 (MH+, 100%), 193 (M-CH═CH2, 42%).
Hydrazine monohydrate (6.55 ml; 135 mmol) is added over the course of 10 minutes to a suspension of WP18 prepared according to example 2 (9.92 g, 45.035 mmol) in absolute ethanol (75 ml). The mixture quickly becomes homogeneous, then a yellow precipitate slowly forms. After 24 hours, the precipitate is filtered, washed successively with ethanol then with diethyl ether and is dried to yield 6.838 g (79%) of a yellow solid. δH (300 MHz, D20) 7.66 (s; 4H).
Terephthalamidrazone WP29 prepared according to example 3 (1.00 g, 5.203 mmol) is added all at once to a solution of benzyl (2.455 g, 11.67 mmol) in ethanol (100 ml). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed successively with ethanol then with diethyl ether and is dried to yield 2.587 g (92%) of a yellow solid. mp=321° C.; δH (300 MHz, DMSO-d, 120° C.) 7.42-7.52 (m; 12H), 7.62 (m; 4H), 7.71 (m; 4H), 8.81 (s; 4H); δC (75 MHz, DMSO-d, 120° C.) 129.2 (1), 129.3 (1), 130.2 (1), 130.3 (1), 130.5 (1), 131.4 (1), 136.5 (0), 136.6 (0), 138.4 (0), 156.5 (0), 156.9 (0), 161.3 (0); MS (Nanospray) m/z 1081 (2M+H+, 22%), 541 (MH+, 41%).
A mixture of 1,2-bis(4-methoxyphenyl)-ethane-1,2-dione prepared according to example 1 (7.275 g, 26.91 mmol) and pyridine hydrochlorate (15.55 g, 134.5 mmol) under an atmosphere of nitrogen is heated to 180° C. for 2 days. After returning to ambient temperature, the mixture is diluted with ethyl acetate and water. The aqueous phase is extracted with ethyl acetate and the recombined organic phases are dried on magnesium sulfate, filtered and concentrated under reduced pressure. The residue is purified by flash chromatography on a silica gel (petroleum ether/ethyl acetate 10/1 to 2/1) to yield 5.789 g (89%) of a white solid. δH (300 MHz, MeOH-d) 6.91 (d; J 9.0; 4H), 7.82 (d; J 9.0; 4H).
To a mixture of tetraethylene glycol monomethyl ether (3.00 g, 14.406 mmol) and soda (0.865 g, 21.6 mmol) diluted in THF (33 ml) and water (4 ml) cooled to 0° C., a solution of p-toluenesulfonic acid chloride (3.021 g, 15.8 mmol) in THF (4 ml) is slowly added. After 3 hours of stirring at 0° C., the mixture is poured into iced water (10 ml) and is diluted by dichloromethane. The aqueous phase is extracted with dichloromethane and the recombined organic phases are washed with water then with a NaCl-saturated solution, dried on MgSO4, filtered and concentrated under reduced pressure. The residue is purified by flash chromatography on a silica gel (petroleum ether/ethyl acetate 1/1 to 1/4) to yield 4.234 g (82%) of a colorless oil. δH (300 MHz, CDCl3) identical to the literature.
To a solution of WP32 prepared according to example 5 (600 mg, 2.47 mmol) in ethanol (20 ml), terephthalamidrazone WP29 prepared according to example 3 (190 mg, 0.991 mmol) is added all at once. The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, successively washed with ethanol then with diethyl ether and is dried to yield 479 mg (80%) of a yellow solid. δH (300 MHz, DMSO-d, 25° C.) 6.79-6.84 (m; 8H), 7.44 (d; J 8.4; 4H), 7.58 (d; J 8.4; 4H), 8.71 (s; 4H), 10.03 (sl; 4H); MS (Nanospray) m/z 605 (MH+, 53%)
1,2-bis(4-methoxyphenyl)-ethane-1,2-dione prepared according to example 1 (1.135 g, 4.687 mmol) and then potassium carbonate (3.239 g, 23.4 mmol) are added successively to a solution of tosylate WP33 prepared according to example 6 (3.737 g, 10.3 mmol) in DMF (50 ml). The mixture is stirred at 50° C. for 4 hours. After returning to ambient temperature, the mixture is poured into iced water and extracted several times with ethyl acetate. The recombined organic phases are washed several times with a NaHCO3— saturated solution, then with brine. After drying on MgSO4, filtration and concentration under reduced pressure, the residue obtained is purified by flash chromatography on a silica gel (ethyl acetate, then dichloromethane/methanol 1% to 1.5%) to yield 1.568 g (54%, not optimized) of a yellow oil. δH (300 MHz, CDCl3) 3.36 (s; 6H), 3.51 (m; 4H), 3.51-3.71 (m; 20H), 3.87 (m; 4H), 4.19 (m; 4H), 6.97 (d, J 8.8; 4H), 7.92 (d, J 8.8; 4H); MS (Electrospray) m/z 623 (MH+, 100%).
Soda (726 mg, 18.1 mmol) is added to a solution of 1,2-bis(4-methoxyphenyl)-ethane-1,2-dione prepared according to example 1 (2.00 g, 8.25 mmol) in DMF (50 ml). The mixture is stirred for 5 minutes at ambient temperature, then 1-iodooctadecane (9.4 g, 24.7 mmol) is added over the course of 1 minute. After 3 hours of stirring to 60° C., the mixture is cooled. The precipitate obtained is filtered, washed successively with DMF then with ethanol and dried under a vacuum to yield 3.792 g (61%) of a white solid. mp 87° C.; δH (300 MHz, C6D6) 0.90 (t; J 6.0; 6H), 1.18-1.42 (m; 60H), 1.51 (m; 4H), 3.46 (t; J 6.5; 4H), 6.64 (d; J 9.0; 4H), 8.09 (d; J 9.0; 4H); MS (Electrospray) m/z 1493 (2M+H+, 5%), 747 (MH+, 26%).
Terephthalamidrazone WP29 prepared according to example 3 (200 mg, 1.04 mmol) in ethanol (20 ml) is added all at once to a solution of WP37 prepared according to example 9 (1.71 g, 22.88 mmol). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered and washed with ethanol, then purified by flash chromatography on a silica gel (toluene, then toluene/methanol 1% to 2%) to yield 1.409 g (84%) of a yellow solid. δH (300 MHz, C6D6) 0.91 (m; 6H), 1.18-1.42 (m; 120H), 1.51 (m; 8H), 3.60 (m; 8H), 6.75 (d; J 9.0; 4H), 6.81 (d; J 9.0; 4H), 7.71 (d; J 9.0; 4H), 7.73 (d; J 9.0; 4H), 9.22 (s; 4H); MS (Electrospray) m/z 1615 (MH+, 64%), 1614 (75%), 890 (100%).
Terephthalamidrazone WP29 prepared according to example 3 (1.50 g, 7.804 mmol) is added all at once to a solution of 4,4′-dimethylbenzyl (4.091 g, 17.16 mmol) in ethanol (140 ml). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed successively in ethanol then with diethyl ether and is dried to yield 4.42 g (95%) of a yellow solid. δH (300 MHz, DMSO-d, 120° C.) 2.50 (s; 12H), 7.27 (m; 8H), 7.52 (d; J 8.0; 4H), 7.61 (d; J 8.0; 4H), 8.78 (s; 4H); MS (Nanospray) m/z 1789 (3M+H+, 65%), 1193 (2M+H+, 57%), 597 (MH+, 49%).
Terephthalamidrazone WP29 prepared according to example 3 (1.50 g, 7.804 mmol) is added all at once to a solution of 1,2-bis(4-methoxyphenyl)-ethane-1,2-dione prepared according to example 1 (5.273 g, 19.5 mmol) in ethanol (140 ml). The mixture is heated at reflux for 30 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed successively with ethanol, dichloromethane and diethyl ether then dried to yield 4.087 g (80%) of a yellow solid. δH (300 MHz, DMSO-d, 120° C.) 3.86 (s; 12H), 7.02 (m; 8H), 7.58 (d; J 7.8; 4H), 7.71 (d; J 8.7; 4H), 8.77 (s; 4H); MS (Nanospray) m/z 661 (MH+, 8%), 332 (55%).
Terephthalamidrazone WP29 prepared according to example 3 (64 mg, 0.337 mmol) is added all at once to a solution of WP36 prepared according to example 8 (524 mg, 0.842 mmol) in ethanol (7 ml). The mixture is heated at reflux for 30 hours. After returning to ambient temperature, the solvent is concentrated under reduced pressure and the residue is purified directly by flash chromatography on a silica gel (ethyl acetate, then ethyl acetate/methanol 2% to 6%) to yield 350 mg (76%) of a yellow solid. δH (300 MHz, CDCl3) 3.37 (s; 12H), 3.54 (m; 8H), 3.60-3.74 (m; 40H), 3.88 (m; 8H), 4.18 (m; 8H), 6.93 (m; 8H), 7.60 (d, J 8.8; 4H), 7.92 (d, J 8.8; 4H); 8.82 (s; 4H); δC (75 MHz, CDCl3) 58.9 (3), 67.3 (2), 67.4 (2), 69.4 (2), 69.5 (2), 70.4 (2), 70.5 (2), 70.7 (2), 71.8 (2), 114.5 (1), 114.6 (1), 128.0 (1), 128.1 (1), 128.4 (1), 130.6 (1), 131.4 (1), 137.5 (1), 154.2 (0), 154.7 (0), 159.9 (0), 160.1 (0), 160.9 (0); MS (Electrospray) m/z 1387 (M+Na+, 24%), 1366 (MH+, 100%).
Terephthalamidrazone WP29 prepared according to example 3 (200 mg, 1.040 mmol) is added all at once to a solution of 4,4′-dibromobenzyl (1.149 g, 3.12 mmol) in ethanol (20 ml). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed successively with ethanol, dichloromethane and diethyl ether then dried to yield 757 mg (85%) of a yellow solid. <δH (300 MHz, DMSO-d, 120° C.) 7.56-7.69 (m; 8H), 7.80-7.88 (m; 8H), 8.80 (s; 4H).
Dodecanoyl chloride (44.1 ml, 191.1 mmol) is slowly added to a mixture of bromobenzene (60 g, 382.1 mmol) and aluminum chloride (30.57 g, 229.3 mmol). The mixture is stirred at 50° C. for 1 hour. After cooling, the mixture is poured into iced water and extracted with dichloromethane. The recombined organic phases are washed with 2 N HCl then with brine and are dried on magnesium sulfate. After filtration and concentration under reduced pressure, the residue is taken up in ethanol. The resulting precipitate is filtered, washed several times in ethanol and dried to yield 36.9 g (57%, not optimized) of pure product in the form of a white solid (no recrystallization). Analyses identical to the literature.
Hydrazine monohydrate (23.6 ml, 4.5 eq) and then potash (24.3 g, 4 eq) are added to a solution of WP59 prepared according to example 15 (36.5 g, 108.87 mmol) in tri(ethylene glycol) (180 ml). The mixture is stirred at reflux for approximately 15 hours. After cooling, it is poured into water, acidified with concentrated HCl, then extracted with dichloromethane. The organic phase is washed with water, dried on magnesium sulfate, filtered and concentrated under reduced pressure. The residue is purified by flash chromatography on a silica gel (pentane 100%) to yield 21.2 g (60%, not optimized) of a colorless oil. Analyses identical to the literature.
A suspension of isophthalonitrile (12.81 g, 100 mmol) in a mixture of dry 1,4-dioxane (100 ml)/absolute ethanol (14.6 ml) cooled to 0° C. is bubbled with HCl gas for 48 hours, during which time the temperature returns to ambient temperature. After 4 additional days of stirring, the white solid obtained (approximately 28 grams of di-chlorohydrate salt) is filtered and washed with diethyl ether. The neutralization of this salt placed in suspension in diethyl ether is carried out by slowly adding potassium an aqueous carbonate solution (30% by weight) up to basic pH. The organic phase is separated, dried on MgSO4, filtered and concentrated under reduced pressure to yield a white solid (yield>90%). δH (300 MHz, CDCl3) 1.44 (t; J 6.9; 6H), 4.32 (q; J 6.9; 4H), 7.47 (t; J 7.5; 1H), 7.86 (d; J 7.5; 2H), 8.16 (s; 1H); SM (Electrospray) m/z 221 (MH+, 100%).
Hydrazine monohydrate (485 μl, 9.98 mmol) is added over the course of 10 minutes to a suspension of diethyl isophthalimidate WP73 prepared according to example 17 (1.0 g, 4.53 mmol) in dry acetonitrile (18 ml) cooled to 0° C. After 48 hours of stirring, the precipitate formed is filtered, washed with acetonitrile and dried to yield 630 mg (72%) of a yellow solid. δH (300 MHz, D2O) 7.50 (t; J 7.3; 1H), 7.67 (d; J 7.3; 2H), 7.80 (s; 1H); SM (in solution in D2O) (EI) m/z 199 (100%).
WP75 prepared according to example 18 (620 mg, 3.225 mmol) is added all at once to a solution of benzyl (1.491 g, 7.09 mmol) in ethanol (60 ml). The mixture is heated at reflux for 20 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed successively with ethanol then with diethyl ether and is dried to yield 1.488 g (85%) of a yellow solid. δH (300 MHz, DMSO-d, 120° C.) 7.42-7.52 (m; 12H), 7.61 (d; J 1.2; 4H), 7.63 (d; J 1.5; 4H), 7.90 (t; J 7.3; 1H), 8.81 (d; J 7.3; 2H), 9.77 (s; 1H); MS (Electrospray) m/z 1081 (2M+H+, 74%), 541 (MH+, 100%), 175 (88%).
Terephthalamidrazone WP29 prepared according to example 3 (200 mg, 1.040 mmol) is added all at once to a solution of 4,4′-difluorobenzyl (769 mg, 3.12 mmol) in ethanol (20 ml). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed successively with ethanol then with diethyl ether and is dried under a vacuum to yield 541 mg (85%) of a yellow solid. δH (300 MHz, DMSO-d, 120° C.) 7.56-7.69 (m; 8H), 7.80-7.88 (m; 8H), 8.80 (s; 4H). MS (Electrospray) m/z 613 (MH+, 100%), 178 (34%).
A solution of s-BuLi (1.3 M in cyclohexane, 5.4 ml, 7.02 mmol) is slowly added to a solution of 4-bromo-n-hexylbenzene (1.68 g, 7.02 mmol) in THF (9 ml) at −78° C. and under an atmosphere of nitrogen. After one hour of stirring, the mixture is transferred using a cannula to a suspension of 1,4-dimethylpiperazine-2,3-dione (450 mg, 3.166 mmol) in THF (11 ml) cooled to −40° C. After returning to ambient temperature, the mixture is stirred for 15 hours then treated with 5 ml of 2 N HCl. After dilution with dichloromethane and stirring, the organic phase is separated, washed with 2 N HCl then with water, and dried on magnesium sulfate. After filtration and concentration, the residue is purified by flash chromatography on a silica gel (pentane/ethyl acetate 100/0; 4/1; 3/1; 2/1) to yield 820 mg (68%) of a yellow oil. δH (300 MHz, CDCl3) 0.87 (t; J 6.6; 6H), 1.20-1.40 (m; 12H), 1.50-1.70 (m; 4H), 2.67 (t; J 7.5; 4H), 7.30 (d; J 8.4; 4H), 7.87 (d; J 8.4; 4H); MS (IC) m/z 379 (MH+, 100%).
Terephthalamidrazone WP29 prepared according to example 3 (43 mg, 0.22 mmol) is added all at once to a solution of WP94 prepared according to example 21 (187 mg, 0.49 mmol) in ethanol (5 ml). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed with ethanol and dried to yield 144 mg (74%) of a yellow solid. δH (300 MHz, CDCl3) 0.88 (m; 12H), 1.20-1.40 (m; 24H), 1.45-1.70 (m; 8H), 2.65 (t; J 7.8; 8H), 7.18 (m; 8H), 7.57 (d; J 8.4; 4H), 7.65 (d; J 7.8; 4H); MS (Electrospray) m/z 1754 (2M+H+, 33%), 877 (MH+, 100%).
Terephthalamidrazone WP29 prepared according to example 3 (24 mg, 0.122 mmol) is added all at once to a solution of 4,4′-chlorobenzyl (75 mg, 0.27 mmol) in ethanol (3 ml). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed successively with ethanol then with diethyl ether and dried under a vacuum to yield a yellow solid (yield not calculated). δH (300 MHz, DMSO-d, 120° C.) 7.50-7.60 (m; 12H), 7.69 (d; J 8.4; 4H), 8.81 (s; 4H).
A solution of potassium cyanide (4.61 g, 70.89 mmol) in water (14 ml) is slowly added to a solution of 4-tert-butylbenzaldehyde (115 g, 708.9 mmol) in a methanol (300 ml)/water (40 ml) mixture. The mixture is stirred at 90° C. for 40 hours. After cooling, the methanol is concentrated under reduced pressure and the residue is taken up in dichloromethane and water. After three extractions with dichloromethane, the recombined organic phases are dried on magnesium sulfate, filtered and concentrated under reduced pressure. Pentane (approximately 800 ml) is then added, and the resulting precipitate is filtered, washed several times in pentane and dried to yield 55.23 g (49%, not optimized) of pure product in the form of a white solid. Analyses identical to the literature.
A 15% solution by weight of Dess-Martin periodinane in dichloromethane (100 ml, approximately 46.29 mmol) is added over the course of 10 minutes to a solution of WP101 cooled to 0° C. prepared according to example 24 (12 g, 37.037 mmol) in dry dichloromethane (350 ml). The mixture is stirred overnight, then diluted with dichloromethane and treated with a solution saturated with sodium hydrogen carbonate. After 10 minutes of stirring, the organic phase is separated and the aqueous phase is extracted with dichloromethane. The recombined organic phases are washed with a solution saturated with sodium chloride, filtered and concentrated under reduced pressure. The residue obtained is purified by flash chromatography on a silica gel (pentane/dichloromethane 4/1 to 1.5/1) to yield 10.78 g (90%) of a yellow oil which is solidified under a high vacuum. Analyses identical to the literature.
Terephthalamidrazone WP29 prepared according to example 3 (2.924 g, 15.217 mmol) is added all at once to a suspension of WP103 prepared according to example 25 (10.78 g, 33.47 mmol) in ethanol (250 ml). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed with ethanol and dried to yield 10.56 g (93%) of a yellow solid. δH (300 MHz, CDCl3) 1.35 (s; 36H), 7.42 (m; 8H), 7.63 (d; J 8.1; 4H), 7.71 (d; J 8.4; 4H), 8.85 (s; 4H); MS (Electrospray) m/z 1789 (3M+H+, 65%), 1530 (2M+H+, 71%), 765 (MH+, 100%).
A solution of 4-bromo-dodecylbenzene WP60 prepared according to example 16 (20.19 g, 62.065 mmol) in THF (80 ml) is slowly added to a solution of 30 ml of dry THF and s-BuLi (1.3 M in cyclohexane, 47.7 ml, 62.065 mmol) cooled to −78° C. and under a nitrogen atmosphere. After one hour of stirring, the mixture is transferred using a cannula to a suspension of 1,4-dimethylpiperazine-2,3-dione (107 mg, 0.7539 mmol) in THF (2.7 ml) cooled to −40° C. The mixture is stirred for 15 hours then treated with 2 N HCl. After dilution with dichloromethane and stirring, the organic phase is separated, washed with 2 N HCl then with water, and is dried on magnesium sulfate. After filtration and concentration, the residue is purified by flash chromatography on a silica gel (pentane/ethyl acetate 100/0; 10/1; 4/1; 3/1; 2/1) to yield 2.77 g (18%) of a yellow oil. Analyses identical to the literature.
Terephthalamidrazone WP29 prepared according to example 3 (275 mg, 1.431 mmol) is added all at once to a solution of WP105 prepared according to example 27 (1.649 g, 3.147 mmol) in ethanol (70 ml). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed with ethanol and dried to yield 1.38 g (80%) of a yellow solid. δH (300 MHz, CDCl3) 0.87 (m; 12H), 1.20-1.40 (m; 72H), 1.50-1.70 (m; 8H), 2.63 (t; J 7.5; 8H), 7.20 (m; 8H), 7.57 (d; J 8.1; 4H), 7.65 (d; J 8.4; 4H); MS (Electrospray) m/z 1213.9 (MH+, 100%).
A suspension of terephthalonitrile (2.5 g, 12.24 mmol) in absolute ethanol (30 ml) cooled to 0° C. is bubbled with HCl gas for 24 hours, during which time the temperature returns to ambient temperature. The white solid obtained is then filtered and washed with ethanol. The neutralization of this salt dissolved in a minimum of water at 0° C. is carried out by adding a solution of 0° C. K2CO3 (30% by weight) up to basic pH. The white solid obtained is dissolved in dichloromethane. The aqueous phase is separated then the organic phase is dried on MgSO4, filtered and concentrated to yield a white solid (yield>90%). δH (300 MHz, CDCl3) 1.4 (t; J 7.2; 6H), 4.34 (q; J 7.2; 4H), 7.63 (d; J 8.7; 4H), 7.83 (d; J 8.7; 4H).
A mixture of 4-methyl valeric acid (15 g, 129.1 mmol) and thionyl chloride (10.8 ml, 148 mmol) is heated at reflux for 90 minutes. The excess thionyl chloride is distilled under reduced pressure, then the residue is taken up in 48 ml of bromobenzene. After cooling to 0° C., anhydrous aluminum chloride (13.8 g, 103.5 mmol) is added to the solution. The mixture is stirred at ambient temperature for 80 hours, then treated with the addition of iced water, then with 20 ml of concentrated HCl. The organic phase is separated and the aqueous phase extracted by Et2O. The recombined organic phases are washed successively with water then with a solution saturated with sodium chloride, dried on MgSO4, filtered and concentrated under reduced pressure. The residue is purified either by a) distillation (approximately 80° C./0.01 mm) or b) chromatography on a silica gel (pentane 100% then pentane/ethyl acetate 10/1) followed by filtration, water wash and drying, to yield 20.337 g (62%, not optimized) of a colorless solid. Analyses identical to the literature.
A 2 M solution of trimethylaluminum in hexane (10.5 ml, 2 eq) is slowly added to a solution of ketone WP132 prepared according to example 30 (2.675 g, 10.49 mmol) in chlorobenzene (4 ml) and water (100 μl) under a nitrogen atmosphere and cooled to 0° C. The hexane is then distilled and then the solution is heated at reflux for 80 hours. After cooling, the mixture is treated with the slow addition of water, then with 2 N HCl and is heated until the salts are dissolved. After cooling, the mixture is extracted several times with Et2O. The recombined organic phases are washed successively with water then with a solution saturated with NaCl, dried on magnesium sulfate, filtered and concentrated under reduced pressure. The residue is then distilled (approximately 100° C./0.16 mm) to yield a mixture of products which is dissolved in 10 ml of dichloromethane, treated with 1.0 g of M-CPBA and stirred for 12 hours. After concentration under reduced pressure, the residue is purified by chromatography on a silica gel (pentane 100%) to yield 1.143 g (40%, not optimized) of a colorless liquid. Analyses identical to the literature.
Hydrazine monohydrate (637 μl, 13.1 mmol) is added over the course of 10 minutes to a suspension of WP129 prepared according to example 29 (1.296 g, 4.37 mmol) in absolute ethanol (7 ml). After 24 hours of stirring, the precipitate is filtered, washed successively with ethanol then with diethyl ether and is dried to yield 1.077 g (92%) of a yellow solid. δH (300 MHz, DMSO) 5.00 (brs; 4H), 5.62 (s; 4H), 7.66 (d; J 8.7; 4H), 7.78 (d; J 8.7; 4H); MS (Electrospray) m/z 269 (MH+, 100%).
WP134 prepared according to example 32 (300 mg, 1.12 mmol) is added all at once to a solution of benzyl (589 mg, 2.79 mmol) in ethanol (20 ml). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed successively with ethanol then with diethyl ether and is dried to yield 548 mg (80%) of a yellow solid. δH (300 MHz, DMSO-d, 120° C.) 7.40-7.57 (m; 12H), 7.60 (m; 4H), 7.68 (m; 4H), 8.10 (d; 4H), 8.77 (d; 4H). MS (Electrospray) m/z 617 (MH+, 10%), 457 (26%), 190 (100%).
Soda (1.24 g, 30.8 mmol) is added to a solution of WP32 prepared according to example 5 (3.00 g, 12.4 mmol) in DMF (75 ml). The mixture is stirred for 5 minutes at ambient temperature, then 2-ethylhexyl bromide (6.6 ml, 37.1 mmol) is added over the course of 1 minute. After 60 hours of stirring at 60° C., the mixture is cooled. The mixture is poured into iced water and extracted by ethyl acetate. The organic phase is washed several times with a solution saturated with sodium bicarbonate, dried on sodium sulfate, filtered and concentrated. The residue is purified by flash chromatography on a silica gel (pentane 100% then pentane/ethyl acetate 23/1) to yield 4.879 g (85%) of a yellow liquid. δH (300 MHz, CDCl3) 0.90 (m; 12H), 1.25-1.35 (m; 8H), 1.45 (m; 8H), 1.75 (m; 2H), 3.91 (d; J 6.0; 4H), 6.94 (d; J 9.0; 4H), 7.92 (d; J 9.0; 4H); MS (Electrospray) m/z 954 (2M+H+, 100%), 467 (MH+, 33%).
Terephthalamidrazone WP29 prepared according to example 3 (300 mg, 1.56 mmol) is added all at once to a solution of WP141 prepared according to example 34 (1.821 g, 1.52 mmol) in ethanol (40 ml). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed successively with ethanol then with diethyl ether and is dried to yield 1.452 g (88%) of a yellow solid. δH (300 MHz, CDCl3) 0.90 (m; 24H), 1.25-1.60 (m; 32H), 1.74 (m; 4H), 3.89 (d; J 6.0; 8H), 6.92 (m; 8H), 7.63 (d; J 8.4; 4H), 7.74 (d; J 8.4; 4H), 8.82 (s; 4H); MS (Electrospray) m/z 1053 (MH+, 100%).
Potassium carbonate (900 mg, 7.1 mmol) and then (S)-2-octyl tosylate(10) (740 mg, 2,6 mmol) are added to a solution of WP32 prepared according to example 5 (286 mg, 1.184 mmol) in DMF (6 ml). After 15 hours of stirring at 50° C., the mixture is cooled then poured into iced water and extracted by ethyl acetate. The organic phase is washed several times with a solution saturated with sodium bicarbonate, dried on sodium sulfate, filtered and concentrated. The residue is purified by flash chromatography on a silica gel (pentane 100% then pentane/ethyl acetate 20/1) to yield 406 mg (74%) of a yellow oil. δH (300 MHz, CDCl3) 0.80-0.93 (m; 6H), 1.20-1.40 (m; 12H), 1.31 (d; J 6; 6H), 1.55 (m; 4H), 1.73 (m; 4H), 4.46 (m; 2H), 6.91 (d; J 9.3; 4H), 7.92 (d; J 9.3; 4H); MS (Electrospray) m/z 955 (2M+Na+, 100%), 467 (MH+, 56%).
Terephthalamidrazone WP29 prepared according to example 3 (69 mg, 0.355 mmol) is added all at once to a solution of WP145 prepared according to example 36 (398 mg, 0.85 mmol) in ethanol (8 ml). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed successively with ethanol then with cold pentane and dried to yield a yellow solid (yield not calculated). δH (300 MHz, CDCl3) 0.80-0.95 (m; 12H), 1.20-1.53 (m; 24H), 1.31 (d; J 6; 12H), 1.60 (m; 8H), 1.75 (m; 8H), 4.42 (m; 4H), 6.88 (d; J 9.0; 4H), 6.91 (d; J 9.0; 4H), 7.63 (d; J 9.0; 4H), 7.73 (d; J 9.0; 4H), 8.82 (s; 4H); MS (Electrospray) m/z 1053 (MH+, 100%).
A solution of s-BuLi (1.3 M in cyclohexane, 2.9 ml, 3.71 mmol) is added slowly to a solution of WP133 prepared according to example 31 (1.0 g, 3.71 mmol) in anhydrous THF (4.6 ml) at −78° C. and under a nitrogen atmosphere. After 1 hour of stirring during which 3 additional ml of THF are added, the mixture is heated to approximately 0° C. then transferred using a cannula to a suspension of 1,4-dimethylpiperazine-2,3-dione (240 mg, 1.688 mmol) in THF (6 ml) cooled to 0° C. After returning to ambient temperature, the mixture is stirred for 3 hours then treated with 2 N HCl. After dilution with Et2O, the organic phase is separated and the aqueous phase is extracted twice with Et2O. The recombined organic phases are washed with water and then with a solution saturated with NaCl and are dried on magnesium sulfate. After filtration and concentration, the residue is purified by flash chromatography on a silica gel (pentane/ethyl acetate 100/0; 6/1; 4/1) to yield 523 mg (71%, not optimized) of a yellow oil. δH (300 MHz, CDCl3) 0.80 (d; J 6.0; 12H), 0.85-0.97 (m; 4H), 1.3 (s; 12H), 1.40 (sept.; J 6.0; 2H), 1.55-1.70 (m; 4H), 7.45 (d; J 8.7; 4H), 7.91 (d; J 8.7; 4H).
Terephthalamidrazone (104 mg, 0.544 mmol) is added all at once to a solution of WP150 prepared according to example 38 (520 mg, 1.196 mmol) in ethanol (10 ml). The mixture is heated at reflux for 15 hours. After returning to ambient temperature, the precipitate obtained is filtered, washed with ethanol and dried to yield 348 mg (65%, not optimized) of a yellow solid. δH (300 MHz, CDCl3) 0.81 (d; J 6.0; 24H), 0.90-0.10 (m; 8H), 1.31 (s; 24H), 1.40 (sept.; J 6.0; 4H), 1.53-1.70 (m; 8H), 7.33 (d; J 8.7; 4H), 7.34 (d; J 8.7; 4H), 7.58 (d; J 8.7; 4H), 7.66 (d; J 8.7; 4H); MS (Electrospray) m/z 1978 (2M+H+, 30%), 989 (MH+, 100%).
Below are found the physicochemical studies carried out on the compounds which are objects of the present invention, in comparison with the following commercial filters:
The calculation of the molar extinction coefficient (ε) is made from the Beer-Lambert law:
Wherein:
The molar extinction coefficient can be expressed with respect to a given mass of the product. It thus makes it possible to be able to compare the coefficients of extinction between products for the same given quantity. This quantity is 1% by weight. The molar extinction coefficient thus becomes the specific absorbance (A1cm1%).
It is expressed as follows:
Wherein:
The spectral characteristics of the compounds in comparison with commercial filters at a concentration of 10 μg/ml are summarized in tables 2-1 and 2-2.
Procedure: The products are dissolved in ethyl acetate to a concentration of 10 μg/ml. The spectra are measured using a dual-beam spectrophotometer (Varian CARY 50 Scan) between 290 nm and 400 nm.
The products tested are classified according to spectral distribution in UVA and UVB in a range from 290 nm to 400 nm. It is possible to differentiate them according to their spectral distribution:
Products with a narrow spectrum:
Products with a broad spectrum:
WP89, WP96, WP100, WP104, WP107, WP135, WP144, WP149, WP151, WP35, WP39, WP41, WP52 and WP30 absorb in UVB and UVA (see
WP76 absorbs in UVB (see
Table 3 summarizes the spectral distributions of the compounds tested.
The in vitro methods of determining the protective effectiveness of sun products consist of measuring by transmission spectrophotometry the absorption spectrum of the filter in solution or of the product applied on a substrate with the aim of simulating the surface of the skin. The effectiveness against UVB and/or UVA rays, or the effect on the cutaneous response, are then determined by calculation, taking into account or not the UV radiation action spectrum for the damage considered.
The Sayre/Agin and Diffey/Robson method, used since the 1990s, involves a comparative measurement, with the aid of an integrating-sphere spectroradiometer, of the transition from 290 nm to 400 nm in 5 nm steps, the sample being subjected to UV radiation from a stable known source covering the whole of the UV spectrum (unfiltered xenon).
Diffey and Robson evaluate the erythemal response by the following calculation:
E(λ)=spectral irradiation in W(m-2) (nm−1) at 40° N sun at 20° zenith angle
N(λ)=number of values for a given wavelength
The Diffey and Robson formula makes it possible to determine SPF from the measurement of transmittance between 290 nm and 400 nm. Transmittance is measured in solution in ethyl acetate at a concentration of 10 μg/ml using a UV-visible spectrophotometer (Varian CARY 50 Scan).
T(λ)=transmittance at wavelength λ
The results of the measurements taken are summarized in table 5.
A Suntest CPS+(Atlas, Linsengenicht/Altenhasslan, Germany) was used. The Suntest makes it possible to reproduce the solar spectrum and thus to carry out exposures inside at any time without weather constraints.
Setting the MED (Minimal Erythemal Dose):
The radiance of the solar simulator was carefully measured with a spectroradiometer (MSS 2044, Bielefeld, Germany). UVB and UVA intensities were 0.49 mW/cm2 and 6.32 mW/cm2, respectively. The MED value defined by COLIPA is 5.6 J/cm2 in total UV (22). The UV total (UVA+UVB) accounts for 14.8% of the energy delivered by the lamp (power 460 W/m2). An irradiation dose equivalent to 1 MED corresponds to 37.83 J/cm2 (in total spectrum) delivered by the lamp.
The Suntest test duration is calculated using the following formula:
t=H/E
with:
The setting of the MED on the Suntest and the correspondence with sun intensity at 3 seaside resorts are indicated in table 6.
Procedure:
The solutions of the compounds are prepared at a concentration of 500 μg/ml in methanol. 50 μl (25 μg) of each solution are deposited in a crystallizer, then irradiated in the Suntest at 5, 10 and/or 20 MED. A non-irradiated control is prepared (deposit of 50 μl of solution and addition of 2.450 ml of methanol). The solvent evaporates during irradiation and the products are taken up in 2.5 ml of methanol. After irradiation, the absorbance of each solution is measured with the UV-visible spectrophotometer (Varian CARY 50 Scan).
The photostability measurement results for the compounds of formula (I) are summarized in table 7.
The solubility results for solvents or excipients used in cosmetics are summarized in table 8.
| Number | Date | Country | Kind |
|---|---|---|---|
| 04 04811 | May 2004 | FR | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/FR2005/001132 | 5/4/2005 | WO | 00 | 1/17/2008 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2005/121128 | 12/22/2005 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3211729 | Siegrist et al. | Oct 1965 | A |
| 5202471 | Chandraratna | Apr 1993 | A |
| 6193960 | Metzger et al. | Feb 2001 | B1 |
| Number | Date | Country |
|---|---|---|
| 247 899 | Jul 1987 | DE |
| 0 818 950 | Jan 1998 | EP |
| 2 803 194 | Jul 2001 | FR |
| Number | Date | Country | |
|---|---|---|---|
| 20080267892 A1 | Oct 2008 | US |
